NCT06250192

Brief Summary

A randomized controlled trial evaluating whether a patient-centered virtual educational tool based on small videos focusing on optimization of mental health, diet, physical activity, self-adjustment of insulin dose and use of diabetes technology in addition to usual individual face-to-face education, will improve glycemic control and pregnancy outcome in women with pre-existing diabetes mellitus compared to women receiving usual individual face-to-face education alone.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
502

participants targeted

Target at P75+ for not_applicable diabetes-mellitus

Timeline
0mo left

Started Sep 2023

Typical duration for not_applicable diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress98%
Sep 2023Jun 2026

Study Start

First participant enrolled

September 1, 2023

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

February 1, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 8, 2024

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Last Updated

December 12, 2025

Status Verified

November 1, 2025

Enrollment Period

2.8 years

First QC Date

February 1, 2024

Last Update Submit

December 4, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Birthweight standard deviation score

    Offspring birth weight adjusted for gestational age and gender (standard deviation (SD) score)

    At delivery

Secondary Outcomes (14)

  • HbA1c during pregnancy

    At inclusion, at 21 weeks, at 33 weeks and at 35 weeks

  • Continuous glucose monitoring data

    Throughout pregnancy and 1 month post delivery

  • Severe hypoglycemia

    2 years

  • Maternal weight gain

    At inclusion, at 21 weeks, at 33 weeks, 35 weeks and one month after delivery

  • Individuel insulin pump settings in women using insulin pump

    At inclusion, at 21 weeks, at 33 weeks, 35 weeks, at delivery and one month after delivery

  • +9 more secondary outcomes

Study Arms (2)

Intervention with patient-centered virtuel educational tools

EXPERIMENTAL

Patient randomized to intervention with patient-centered virtuel educational tools based on small videos

Other: Virtuel education

Control: Women were randomized to usal care

NO INTERVENTION

Randomized to standard treatment without acces to virutel educational tools

Interventions

Randomization to virtuel education based on a tool of small videos accessible via smartphones

Intervention with patient-centered virtuel educational tools

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women, age ≥ 18 years
  • Type 1 diabetes, type 2 diabetes or other types of pre-existing diabetes (e.g., maturity onset diabetes of the young (MODY))

You may not qualify if:

  • A diagnosis with severe mental or psychiatric barriers or a concurrent disease based on the decision of the investigator
  • No proficiency in Danish to understand oral and written information
  • To secure independent observations, women can be randomized in the ETOS-DM study only once.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Pregnant Women with Diabetes

Copenhagen, Denmark

Location

MeSH Terms

Conditions

Diabetes MellitusPregnancy Complications

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Elisabeth Mathiesen

    Rigshospitalet, Denmark

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 1, 2024

First Posted

February 8, 2024

Study Start

September 1, 2023

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

December 12, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations